Parisi, Rose http://orcid.org/0000-0003-2454-6895
Shah, Hemali http://orcid.org/0000-0002-8407-9339
Navarini, Alexander A. http://orcid.org/0000-0001-7059-632X
Muehleisen, Beda
Ziv, Michael
Shear, Neil H. http://orcid.org/0000-0001-9151-1145
Dodiuk-Gad, Roni P. http://orcid.org/0000-0003-2168-3798
Article History
Accepted: 27 March 2023
First Online: 8 May 2023
Declarations
:
: No sources of funding were used to assist in the preparation of this article.
: Roni P. Dodiuk-Gad consults for Janssen, Sanofi, AbbVie, Novartis, Pfizer, La Roche-Posay, Dexcel, and Eli Lilly. Alexander A. Navarini declares being a consultant and advisor and/or receiving speaking fees and/or grants, and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, Biomed, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi, and UCB. Rose Parisi, Hemali Shah, Beda Muehleisen, Neil H. Shear, and Michael Ziv have no relevant conflicts of interest to disclose.
: Not applicable.
: Not applicable.
: Data were derived from public resources.
: Not applicable.
: Conceptualization: All authors. Literature search and data analysis: RP, HS, RPDG. Writing-original draft preparation: RP, HS, RPDG. Writing-review and editing: All authors. Supervision: All authors. All authors have read and agreed to the published version of the manuscript.
Free to read: This content has been made available to all.